19.02.2019 • NewsDede WillamsEniSABIC

Eni and SABIC in Natgas Technology Pact

Eni and SABIC in Natgas Technology Pact
Eni and SABIC in Natgas Technology Pact

As part of a newly agreed joint venture, Italian energy group Eni and Saudi petrochemicals giant SABIC will collaborate on developing a new technology to convert natural gas into synthesis gas that can be processed further into high value-added fuels and chemicals, such as methanol.

To test and display the process, the partnership plans to build an industrial demonstration plant at one of Eni’s production complexes. The technology selected for upgrade will be based on the Short Contact Time Catalytic Partial Oxidation (SCT-CPO) of natural gas initially developed by the Italian group.

The companies said the new technology will help to make cleanest and lower GHG emission fossil fuel in the most efficient way.

Eni said the joint work will utilize SABIC’s short contact time reactor R&D and its own extensive knowledge of integrating gas generation into processes to produce higher end derivatives.

Beyond the conversion and upgrade of synthesis gas and its integration into advanced chemical process, the jointly developed technology also is expected to lowering capital expenditure and operating costs while achieving higher energy efficiency, an improved CO2 footprint and broader feedstock flexibility.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.